Syngene International Limited has appointed Siddharth Mittal as Managing Director & CEO, effective July 1, 2026. The appointment follows Peter Bains's completion of his tenure as Managing Director & CEO on June 30, 2026.
Siddharth joins Syngene with nearly three decades of business leadership experience, having most recently served as Managing Director & CEO at Biocon Limited. During his thirteen years at Biocon, Siddharth held the position of Chief Financial Officer before being appointed Managing Director and CEO.
At Biocon, Siddharth played a pivotal role in shaping the strategic direction, strengthening commercial operations, expanding global market presence, securing key regulatory approvals, and successfully commercializing the GLP-1 portfolio across major international markets. He also led strategic partnerships and commercial initiatives that strengthened the company's competitive position.
Kiran Mazumdar-Shaw, Executive Chairperson of Syngene International, welcomed Siddharth as the new Managing Director & CEO. She praised his ability to lead businesses through change and deliver expressing confidence his leadership will help Syngene unlock its full potential.
On assuming his role, Siddharth Mittal expressed honor in becoming MD & CEO of Syngene, citing the company's exceptional scientific capabilities, talented team, and global customer trust. He stated his immediate priorities include sharpening the commercial edge, strengthening delivery excellence, and bringing greater focus to execution across the business.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.